[go: up one dir, main page]

GB2353472A - Vaccine - Google Patents

Vaccine

Info

Publication number
GB2353472A
GB2353472A GB0027072A GB0027072A GB2353472A GB 2353472 A GB2353472 A GB 2353472A GB 0027072 A GB0027072 A GB 0027072A GB 0027072 A GB0027072 A GB 0027072A GB 2353472 A GB2353472 A GB 2353472A
Authority
GB
United Kingdom
Prior art keywords
agent
binding
etxb
ctxb
vtxb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0027072A
Other versions
GB0027072D0 (en
Inventor
Raymond Timothy Hirst
Neil Andrew Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809958.3A external-priority patent/GB9809958D0/en
Priority claimed from GBGB9812316.9A external-priority patent/GB9812316D0/en
Application filed by University of Bristol filed Critical University of Bristol
Publication of GB0027072D0 publication Critical patent/GB0027072D0/en
Publication of GB2353472A publication Critical patent/GB2353472A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There is disclosed the use of: (i) EtxB, CtxB or VtxB free from whole toxin; (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding; as an immunomodulator for a vaccine against infectious diseases.
GB0027072A 1998-05-08 1999-05-10 Vaccine Withdrawn GB2353472A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9809958.3A GB9809958D0 (en) 1998-05-08 1998-05-08 Vaccine
GBGB9811954.8A GB9811954D0 (en) 1998-05-08 1998-06-03 Vaccine
GBGB9812316.9A GB9812316D0 (en) 1998-06-08 1998-06-08 Cancer vaccines
PCT/GB1999/001461 WO1999058145A2 (en) 1998-05-08 1999-05-10 Immunomodulators for vaccines

Publications (2)

Publication Number Publication Date
GB0027072D0 GB0027072D0 (en) 2000-12-20
GB2353472A true GB2353472A (en) 2001-02-28

Family

ID=27269307

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0027072A Withdrawn GB2353472A (en) 1998-05-08 1999-05-10 Vaccine

Country Status (18)

Country Link
EP (1) EP1075274A2 (en)
JP (1) JP4666761B2 (en)
KR (1) KR20070067719A (en)
CN (1) CN100335130C (en)
AU (1) AU3939499A (en)
BR (1) BR9910305A (en)
CA (1) CA2331832A1 (en)
CZ (1) CZ302333B6 (en)
EA (1) EA004794B1 (en)
GB (1) GB2353472A (en)
HU (1) HUP0104842A3 (en)
IL (1) IL139467A (en)
IS (1) IS5694A (en)
MX (1) MXPA00010934A (en)
NO (1) NO20005599L (en)
NZ (1) NZ507911A (en)
PL (1) PL344519A1 (en)
WO (1) WO1999058145A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20010036917A1 (en) 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
KR20010043441A (en) 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 Immunomodulators for vaccines
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB0030067D0 (en) * 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
RU2325182C2 (en) * 2005-08-08 2008-05-27 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова Российской академии медицинских наук (ГУ НИИВС им. И.И. Мечникова РАМН) Method of acute respiratory diseases prevention during postvaccinal period for children suffering from chronic glomerulonephritis and chronic renal insufficiency
CN111100824B (en) * 2020-01-21 2021-11-05 暨南大学 A strain of Bacillus and its application in denitrification and sulfur removal in aquaculture water

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372928A2 (en) * 1988-12-07 1990-06-13 University Of Leicester Heat-labile toxin B subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
WO1997002045A1 (en) * 1995-07-05 1997-01-23 Oratol Limited Therapeutic agents and autoimmune diseases
EP0919243A1 (en) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
WO1999036088A1 (en) * 1998-01-16 1999-07-22 Maxim Pharmaceuticals, Inc. RECOMBINANT CtB-BASED VACCINES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372928A2 (en) * 1988-12-07 1990-06-13 University Of Leicester Heat-labile toxin B subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
WO1997002045A1 (en) * 1995-07-05 1997-01-23 Oratol Limited Therapeutic agents and autoimmune diseases
EP0919243A1 (en) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
WO1999036088A1 (en) * 1998-01-16 1999-07-22 Maxim Pharmaceuticals, Inc. RECOMBINANT CtB-BASED VACCINES

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Immunology (1997 Aug),91(4),p572-8; Nashar T O et al *
Immunology today (1999 Feb), 20(2), p95-101; Williams N A et al *
Infection and Immunty, US, American Society for Microbiology63(4), p1349-1355 *
Journal of Infectious diseases (1998 Jun), 177(6), p1451-7 Richards C M et al *
Medical Microbiology and Immunology (1998 Jun), 187(1), p3-10; Nashar T O et al *
Society for applied bacteriology symposium series (1998), 27 26s-34s; Hirst T R et al *

Also Published As

Publication number Publication date
CN1308546A (en) 2001-08-15
CZ20004147A3 (en) 2001-05-16
EP1075274A2 (en) 2001-02-14
PL344519A1 (en) 2001-11-05
CN100335130C (en) 2007-09-05
HUP0104842A2 (en) 2002-04-29
IL139467A (en) 2011-11-30
MXPA00010934A (en) 2003-07-14
CZ302333B6 (en) 2011-03-16
EA004794B1 (en) 2004-08-26
NZ507911A (en) 2004-04-30
KR20070067719A (en) 2007-06-28
IL139467A0 (en) 2001-11-25
WO1999058145A2 (en) 1999-11-18
WO1999058145A3 (en) 2000-02-03
HUP0104842A3 (en) 2002-12-28
IS5694A (en) 2000-10-31
EA200001134A1 (en) 2001-08-27
AU3939499A (en) 1999-11-29
GB0027072D0 (en) 2000-12-20
BR9910305A (en) 2001-01-09
CA2331832A1 (en) 1999-11-18
JP4666761B2 (en) 2011-04-06
JP2002514607A (en) 2002-05-21
NO20005599D0 (en) 2000-11-06
NO20005599L (en) 2001-01-08

Similar Documents

Publication Publication Date Title
BG102259A (en) Compostions with controlled paroxetine release
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
MY126559A (en) Fungicidal 2-methoxybenzophenones
HRP20000292B1 (en) 2-Phenyl Substituted Imidazotriazinones as Phosphodiesterase Inhibitors
AU5242000A (en) Nematicidal trifluorobutenes
CA2367983A1 (en) Low stress die attachment
DE69528829D1 (en) PREPARATIONS FOR INHIBITING BONE RESORPTION BROUGHT BY OSTEOCLASTIC
MX9601360A (en) Synergistic stabilizing mixture.
TR200101859T2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MY132529A (en) Paroxetine hydrochloride anhydrate
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB2353472A (en) Vaccine
AR029590A1 (en) ANTIBACTERIALS
WO2001087849A3 (en) Modulators of tnf- alpha signaling
AU1817902A (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
IT249902Y1 (en) ELASTIC SUIT, PARTICULARLY FOR MOTORCYCLIST.
AU2003227595A1 (en) Foam control agents
AU3284000A (en) 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis
EP1026162A4 (en) Antirheumatic
ES2157419T3 (en) ARILAZADIOXACICLOALQUENOS SUBSTITUIDOS, FUNGICIDAS.
DE69930952D1 (en) TAXED RELEASE OF ANTIDEPRESSIVA
EP1470101A4 (en) New opioid derivative
GB2377060A (en) System for ranking financial underwriters
ATE491709T1 (en) PYRROLIDINOHYDROQUINAZOLINES
AU2252997A (en) Antifungal agent

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)